NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction

About this update from Nfl Biosciences Sa

[{"type":"list","items":[{"val":[{"type":"text","content":"A €600,000 "Innovation Advance" repayable advance granted by Bpifrance","length":80,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"€600,000 in bank loans granted by Société Générale and Banque Populaire, the company’s long-standing banking partners","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additional non-dilutive funding expected as well as the Research Tax Credit reimbursement","length":89,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":286,"olType":false},{"type":"text","content":"MONTPELLIER, France, July 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":69,"tagName":"p"},{"type":"text","content":"NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners.","length":273,"tagName":"p"},{"type":"text","content":"NFL Biosciences obtained a €600,000 "Innovation Advance" repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate.","length":375,"tagName":"p"},{"type":"text","content":"This €1.2 million adds to the €3.0 million raised in the oversubscribed capital increase at the end of May 2025. The company also expects to secure additional non-dilutive funding and plans to benefit each year from the reimbursement of a portion of its R&D expenses through the Research Tax Credit. These funds are allocated to the continued development of NFL-101, its proprietary drug indicated for smoking cessation.","length":424,"tagName":"p"},{"type":"text","content":"The company is currently engaged in scientific advice procedures with European regulatory authorities and the FDA. The feedback expected at the end of the summer will enable the company to confirm its development strategy, notably in relation to manufacturing, preclinical and clinical aspects.","length":294,"tagName":"p"},{"type":"text","content":""We would like to sincerely thank Bpifran...

More updates from Nfl Biosciences Sa